What Is Reuterin? Definition and What Research Reports

Definition

Reuterin is the common name for a small antimicrobial compound produced by the gut bacterium Limosilactobacillus reuteri (formerly Lactobacillus reuteri) when it metabolises glycerol. Chemically it is not a peptide and contains no amino acids: it is described in the literature as 3-hydroxypropionaldehyde (3-HPA) existing in a dynamic equilibrium system with its hydrate and dimer, which is why reviews often refer to the "reuterin system" rather than a single molecule. A critical review of the reuterin system described it as a broad-spectrum antimicrobial produced from glycerol by L. reuteri and examined as a food preservative and health-promoting agent (PMID 36553742). Because it originates from a commensal bacterium rather than from synthesis or recombinant expression, reuterin sits in the category of microbiome-derived bioactive metabolites.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any questions about health, supplements or medications. Nothing here describes how any substance should be used.

What Class of Molecule It Is

Reuterin is an aldehyde-based small molecule, not a protein, peptide or peptide fragment. Its production depends on glycerol as a substrate: L. reuteri converts glycerol to 3-hydroxypropionaldehyde via a vitamin B12-dependent glycerol dehydratase. A food chemistry paper on evolved L. reuteri NK45 framed 3-hydroxypropionaldehyde explicitly as a natural food preservative and described bioproduction approaches for it (PMID 41880962).

Why it appears in peptide glossaries

Reuterin is frequently indexed alongside peptides because both belong to the wider category of "bioactive compounds produced by living systems" and because it is sometimes grouped with bacteriocins — which are peptides. That grouping is a taxonomy convenience, not a chemical equivalence. Readers encountering the term in peptide literature should note the distinction: bacteriocins produced by lactobacilli are ribosomally synthesised peptides, whereas reuterin is a non-proteinaceous aldehyde metabolite.

The Producing Organism

Limosilactobacillus reuteri is the only organism the term reuterin is named after. A 2022 review of L. reuteri in health and disease summarised the species across gastrointestinal, immune and metabolic research contexts (PMID 35336098). An in silico genomic and metabolic atlas of the type strain L. reuteri DSM 20016 mapped its metabolic capabilities in relation to human health (PMID 35889060). Separately, researchers reported that L. reuteri DSM 20016 metabolised foodborne heterocyclic aromatic amines, a finding about the organism's broader metabolic repertoire rather than about reuterin itself (PMID 28679205).

Formulation conditions matter to what the organism produces. One study reported that L. reuteri DSM 17938 produced bioactive components during formulation in sucrose (PMID 39458367), illustrating that the metabolite profile attributed to a strain depends on the growth and processing environment.

What the Published Literature Reports

Antimicrobial and biofilm research

The most established line of work concerns antimicrobial activity. The critical review of the reuterin system evaluated its application as a food preservative and as a potential health-promoting agent, noting that activity depends on the equilibrium chemistry of the system rather than a single isolated compound (PMID 36553742). In an oral-health model, researchers reported that glycerol strengthened the probiotic effect of L. reuteri in oral biofilms, describing the combination as a synergistic synbiotic approach (PMID 36075698). That finding is mechanistically consistent with reuterin's glycerol dependence: the substrate is what enables the antimicrobial output.

Cancer cell and tumour models

Two studies have examined reuterin directly in oncology models. A 2022 Cancer Cell paper reported that reuterin in the healthy gut microbiome suppressed colorectal cancer growth through altering redox balance (PMID 34951957). A 2024 Cancer Letters paper reported that reuterin promoted pyroptosis in hepatocellular cancer cells through mtDNA-mediated STING activation and caspase 8 expression (PMID 39153728). Both are preclinical mechanistic investigations in cells and animal models; neither establishes a clinical use, and no dosing information for humans is available in the verified literature summarised here.

Microbiome, immune and lifespan work on the producing strain

Several papers study the bacterium rather than the isolated metabolite. A pilot study reported on the impact of oral administration of L. reuteri LMG-P 27481 on human gut microbiota diversity and function (PMID 41301930). Researchers reported enhancement of immune functions by L. reuteri KBL346 in in vitro and in vivo studies (PMID 38203313). In an invertebrate model, a study reported that probiotic L. reuteri extended the lifespan of Drosophila melanogaster through insulin/IGF-1 signalling (PMID 37163439). These results describe the organism and are not interchangeable with results for purified reuterin.

How the Term Is Used in Research Writing

• As a metabolite name. "Reuterin" refers to the 3-HPA equilibrium system produced by L. reuteri from glycerol (PMID 36553742).
• As a mechanism label. Papers describing microbiome-mediated effects use reuterin to name the specific chemical mediator, as in the colorectal redox-balance work (PMID 34951957).
• As a food-science ingredient. Work on bioproduction of 3-hydroxypropionaldehyde positions it as a natural preservative candidate (PMID 41880962).
• Loosely, as a shorthand for "what L. reuteri does." This usage is imprecise, since many reported strain effects — immune, microbiome and lifespan outcomes — were attributed to the organism rather than to isolated reuterin (PMID 38203313).

Limits of the Current Evidence

The published record on reuterin as an isolated compound is concentrated in in vitro, animal and food-science settings. The cancer-model reports describe mechanisms — redox alteration and pyroptosis signalling — in preclinical systems (PMID 34951957, PMID 39153728). Human work in the verified set involves oral administration of live L. reuteri strains and reports microbiome composition and function endpoints in a pilot format (PMID 41301930). Reuterin is not an approved medicine in any jurisdiction, and this entry makes no statement about how it might be used.

References

• Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance (Cancer Cell, 2022)
• Reuterin promotes pyroptosis in hepatocellular cancer cells through mtDNA-mediated STING activation and caspase 8 expression (Cancer Letters, 2024)
• Limosilactobacillus reuteri in Health and Disease (Microorganisms, 2022)
• In Silico Genomic and Metabolic Atlas of Limosilactobacillus reuteri DSM 20016: An Insight into Human Health (Microorganisms, 2022)
• Enhancement of Immune Functions by Limosilactobacillus reuteri KBL346: In Vitro and In Vivo Studies (International Journal of Molecular Sciences, 2023)
• Application of the Reuterin System as Food Preservative or Health-Promoting Agent: A Critical Review (Foods, 2022)
• Metabolism of Foodborne Heterocyclic Aromatic Amines by Lactobacillus reuteri DSM 20016 (Journal of Agricultural and Food Chemistry, 2017)
• Impact of Oral Administration of Lactobacillus reuteri LMG-P 27481 on Human Gut Microbiota Diversity and Function: A Pilot Study (Biomedicines, 2025)
• Limosilactobacillus reuteri DSM 17938 Produce Bioactive Components during Formulation in Sucrose (Microorganisms, 2024)
• Glycerol strengthens probiotic effect of Limosilactobacillus reuteri in oral biofilms: A synergistic synbiotic approach (Molecular Oral Microbiology, 2022)
• Innovative bioproduction of natural food preservative 3-hydroxypropionaldehyde by evolved Limosilactobacillus reuteri NK45 (Food Chemistry, 2026)
• Probiotic Limosilactobacillus Reuteri (Lactobacillus Reuteri) Extends the Lifespan of Drosophila Melanogaster through Insulin/IGF-1 Signaling (Aging and Disease, 2023)